GlassScriptPhysician profile
Anna M Heider
NPI 1649431404
$1,670.64
in general payments reported to CMS, 2019-2025
15 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $422 · 2023: $814 · 2024: $215 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.18 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $294.29 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $172.75 | 2023-2025 | Zoryve |
| Genzyme Corporation | $148.95 | 2022 | |
| Incyte Corporation | $141.39 | 2022-2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.13 | 2023 | Spevigo |
| Dermavant Sciences, INC. | $96.70 | 2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $95.25 | 2022-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $71.33 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.24 | 2022 | |
| Pfizer INC. | $53.47 | 2022 | |
| Amgen INC. | $35.65 | 2022-2024 | Otezla |
| Leo Pharma INC. | $25.05 | 2022 | |
| Lnhc, INC | $23.91 | 2025 | Zelsuvmi |
| Janssen Biotech, INC. | $13.35 | 2023 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Heider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.